Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Ovarian Serous Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Ovarian Cancer (550)

Ovarian Cancer (550)

›

BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + letrozole + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2	carboplatin + docetaxel + letrozole Sensitive: A2 - Guideline carboplatin + docetaxel + letrozole Sensitive : A2
No biomarker	Ovarian Serous Adenocarcinoma	No biomarker	Ovarian Serous Adenocarcinoma	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
BRAF V600E	Ovarian Serous Adenocarcinoma	BRAF V600E	Ovarian Serous Adenocarcinoma	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1	binimetinib + encorafenib Sensitive: C1 - Off-label binimetinib + encorafenib Sensitive : C1
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2	avutometinib + defactinib Sensitive: C2 – Inclusion Criteria avutometinib + defactinib Sensitive : C2
BRCA2 mutation	Ovarian Serous Adenocarcinoma	BRCA2 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2	ACR-368 Sensitive: C2 – Inclusion Criteria ACR-368 Sensitive : C2
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3	olaparib + ACR-368 Sensitive: C3 – Early Trials olaparib + ACR-368 Sensitive : C3